Cargando…

In response to: PSMA PET/CT cost-effectiveness analysis in the USA: a response to a published commentary

Detalles Bibliográficos
Autores principales:	Holzgreve, Adrien, Kunz, Wolfgang G., Mehrens, Dirk, Unterrainer, Marcus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10547611/ https://www.ncbi.nlm.nih.gov/pubmed/37594497 http://dx.doi.org/10.1007/s00259-023-06398-8

Ejemplares similares

Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial
por: Holzgreve, Adrien, et al.
Publicado: (2023)

(18)F-FDG PET/CT for Response Assessment in Pediatric Sebaceous Carcinoma of the Parotid Gland
por: Holzgreve, Adrien, et al.
Publicado: (2020)

Total Tumor Volume on (18)F-PSMA-1007 PET as Additional Imaging Biomarker in mCRPC Patients Undergoing PSMA-Targeted Alpha Therapy with (225)Ac-PSMA-I&T
por: Unterrainer, Lena M., et al.
Publicado: (2022)

Immature Plasma Cell Myeloma Mimics Metastatic Renal Cell Carcinoma on (18)F-PSMA-1007 PET/CT Due to Endothelial PSMA-Expression
por: Mittlmeier, Lena M., et al.
Publicado: (2021)

(68)Ga-EMP-100 PET/CT—a novel method for non-invasive assessment of c-MET expression in non-small cell lung cancer
por: Unterrainer, Lena M., et al.
Publicado: (2022)

Metabolic patterns on [(18)F]FDG PET/CT in patients with unresectable stage III NSCLC undergoing chemoradiotherapy ± durvalumab maintenance treatment
por: Holzgreve, Adrien, et al.
Publicado: (2023)

PSMA-Expression Is Highly Associated with Histological Subtypes of Renal Cell Carcinoma: Potential Implications for Theranostic Approaches
por: Bui, Vinh Ngoc, et al.
Publicado: (2023)

Feasibility of Different Tumor Delineation Approaches for (18)F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients
por: Mittlmeier, Lena M., et al.
Publicado: (2021)

Molecular Imaging with (18)F-FDG PET/CT and (99m)Tc-MIBI SPECT/CT in Osteitis Fibrosa Cystica Generalisata
por: Holzgreve, Adrien, et al.
Publicado: (2021)

PSMA PET Imaging in Glioblastoma: A Preclinical Evaluation and Theranostic Outlook
por: Kirchner, Maximilian A., et al.
Publicado: (2021)

(18)F-PSMA-1007 PET/CT for response assessment in patients with metastatic renal cell carcinoma undergoing tyrosine kinase or checkpoint inhibitor therapy: preliminary results
por: Mittlmeier, L. M., et al.
Publicado: (2020)

PSMA Expression in Glioblastoma as a Basis for Theranostic Approaches: A Retrospective, Correlational Panel Study Including Immunohistochemistry, Clinical Parameters and PET Imaging
por: Holzgreve, Adrien, et al.
Publicado: (2021)

PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions
por: Unterrainer, Marcus, et al.
Publicado: (2020)

PSMA PET/CT to evaluate response to SBRT for prostate cancer bone metastases
por: Sadetski, Igor, et al.
Publicado: (2021)

Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer
por: Fanti, Stefano, et al.
Publicado: (2020)

Re: The role of (68)Ga-PSMA-PET/CT in radiotherapy planning in prostate cancer
por: Cihan, Yasemin Benderli
Publicado: (2019)

Cost-Effectiveness Analysis of Local Treatment in Oligometastatic Disease
por: Mehrens, Dirk, et al.
Publicado: (2021)

Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy
por: Rogowski, Paul, et al.
Publicado: (2021)

Finger Pain as an Uncommon Primary Manifestation of Lung Carcinoma
por: Holzgreve, Adrien, et al.
Publicado: (2023)

All that Glitters on PSMA is Not a Lesion: An Unusual Artifact on PSMA PET/CT
por: Dev, Indraja D., et al.
Publicado: (2021)

Ga-68-PSMA PET/CT ? or PET/MRI ?, Mp-MRI ? in diagnosis and radiotherapy planning in a patient with prostate cancer
por: Cihan, Yasemin Benderli
Publicado: (2020)

Next-generation PET/CT imaging in meningioma—first clinical experiences using the novel SSTR-targeting peptide [(18)F]SiTATE
por: Unterrainer, Marcus, et al.
Publicado: (2023)

Response to (225)Ac-PSMA-I&T after failure of long-term (177)Lu-PSMA RLT in mCRPC
por: Ilhan, Harun, et al.
Publicado: (2020)

Metastatic-directed therapy using PSMA-PET/CT at PSA relapse
por: Lilleby, Oscar, et al.
Publicado: (2019)

Development of PSMA-PET-guided CT-based radiomic signature to predict biochemical recurrence after salvage radiotherapy
por: Spohn, Simon K. B., et al.
Publicado: (2023)

Correction to: Next‑generation PET/CT imaging in meningioma—first clinical experiences using the novel SSTR‑targeting peptide [(18)F]SiTATE
por: Unterrainer, Marcus, et al.
Publicado: (2023)

Meta-analysis of (18) F-PSMA-1007 PET/CT, (18) F-FDG PET/CT, and (68)Ga-PSMA PET/CT in diagnostic efficacy of prostate Cancer
por: Yu, Wenxiao, et al.
Publicado: (2023)

PSMA PET-CT in the Diagnosis and Staging of Prostate Cancer
por: Combes, Alexander D., et al.
Publicado: (2022)

Musculoskeletal pitfalls in (68)Ga-PSMA PET/CT
por: Pontes, Írline Cordeiro de Macedo, et al.
Publicado: (2023)

Sarcoid-Like Reaction in Non-Hodgkin’s Lymphoma—A Diagnostic Challenge for Deauville Scoring on (18)F-FDG PET/CT Imaging
por: Winkelmann, Michael, et al.
Publicado: (2021)

Detection of Splenic Tissue Using (99m)Tc-Labelled Denatured Red Blood Cells Scintigraphy—A Quantitative Single Center Analysis
por: Holzgreve, Adrien, et al.
Publicado: (2022)

In response to: Anatomy of (18)F-GE180, a failed radioligand for the TSPO protein
por: Albert, Nathalie L., et al.
Publicado: (2020)

Decision-support for treatment with (177)Lu-PSMA: machine learning predicts response with high accuracy based on PSMA-PET/CT and clinical parameters
por: Moazemi, Sobhan, et al.
Publicado: (2021)

Primary Staging of Prostate Cancer Patients with [(18)F]PSMA-1007 PET/CT Compared with [(68)Ga]Ga-PSMA-11 PET/CT
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

Comparison of (68)Ga-PSMA PET/CT and (18)F-PSMA PET/CT of a Patient with Prostate Cancer Recurrence on Urinary Bladder Wall
por: Soydal, Çiğdem, et al.
Publicado: (2023)

Irreversible electroporation for prostate cancer using PSMA PET-CT
por: Shin, Dongho, et al.
Publicado: (2023)

Prognostic implications of dual tracer PET/CT: PSMA ligand and [(18)F]FDG PET/CT in patients undergoing [(177)Lu]PSMA radioligand therapy
por: Michalski, Kerstin, et al.
Publicado: (2020)

Direct comparison of (99m)Tc-PSMA SPECT/CT and (68)Ga-PSMA PET/CT in patients with prostate cancer
por: Albalooshi, Batool, et al.
Publicado: (2020)

Pitfalls in PSMA imaging: [(18)F]rhPSMA-7-PET/CT reveals presence of chrondrosarcoma
por: Feuerecker, B., et al.
Publicado: (2021)

Multiparametric dynamic whole-body PSMA PET/CT using [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007
por: Dias, André H., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3j1eq0ce7403lh3tirasnhqnri